We have previously demonstrated the radiosensitising properties of the poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors olaparib and rucaparib in neuroblastoma and glioma cells, where they act principally by preventing repair of radiation-induced damage [38]. Here, PARP1 is linked to central nervous system cancer.